Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (Spruce)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01829113 |
Recruitment Status :
Completed
First Posted : April 11, 2013
Results First Posted : June 8, 2018
Last Update Posted : June 8, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non Squamous Non Small Cell Lung Cancer | Drug: OGX-427 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 155 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial) |
Actual Study Start Date : | July 2013 |
Actual Primary Completion Date : | April 19, 2017 |
Actual Study Completion Date : | April 19, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: OGX-427
Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
|
Drug: OGX-427
Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
Other Name: apatorsen |
Placebo Comparator: Placebo
Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
|
Drug: Placebo
Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression. |
- Median Progression-Free Survival [ Time Frame: Every 6 weeks for up to 24 months ]Defined as the time (in months) from date of randomization to the date of first observation of progression based on radiological assessment by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1, or date of death from any cause, in the absence of progressive disease (PD) or censored at the date of last adequate tumor assessment. Progressive Disease is defined by RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest (nadir) sum while on study (this includes the baseline sum if that is the smallest on study), or the appearance of one or more new lesions.
- Number of OGX-427 Versus Placebo Participants With an Objective Response [ Time Frame: Every 6 weeks for up to 24 months ]Defined as the number of patients with objective evidence of complete or partial response (CR or PR) using RECIST v 1.1. A CR is the complete disappearance of all target lesions. A PR is a decrease in baseline of 30% or more of the diameter(s) of all target lesions.
- Median Overall Survival [ Time Frame: Every 6 weeks for up to 41 months ]Defined as the time (in months) from date of randomization to date of death from any cause, or censored at the date last known alive.
- Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety. [ Time Frame: Weekly during each 21 days cycle and for 30 days after last dose for up to 29 Months ]A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologic or cytologic diagnosis of advanced NSCLC, excluding squamous cell and small cell histology. Tumors with mixed NSCLC histologies are eligible, as long as the predominant histology is not squamous. If small-cell elements are present or not otherwise specified histologically, the patient is not eligible.
- Metastatic disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).
- No prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy for metastatic disease; previous adjuvant or neoadjuvant therapy for Stage I, II, or III disease is allowed as long as the interval from the end of treatment until disease progression was >12 months.
- No prior radiation therapy to the whole pelvis or to ≥25% of the total bone marrow area. Other radiation therapy must be completed at least 2 weeks prior to study entry. Must have recovered from acute adverse effects prior to study entry.
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
-
Baseline laboratory values as follows:
- Absolute neutrophil count (ANC) ≥1500/μL
- Hemoglobin (Hgb) ≥10 g/dL
- Platelets ≥100,000/μL
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ≤3.0 x the upper limit of normal (ULN); 5 x ULN if known hepatic metastases.
- Total bilirubin ≤1.5 x ULN, unless secondary to Gilbert's disease
- Serum creatinine ≤1.5 x ULN. If creatinine is >1.5, calculate creatinine clearance (CrCl) ≥45 mL/min by the Cockcroft-Gault method:
Glomerular Filtration Rate (GFR) = (140-age) x (weight/kg) x (0.85 if female)/(72 x serum creatinine mg/dL)
- Fertile male patients willing to use adequate contraceptive measures.
- Female patients who are not of child-bearing potential, and fertile female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of randomization.
- Life expectancy ≥ 12 weeks.
- Must be ≥18 years of age at the time of consent.
- Willingness and ability to comply with trial and follow-up procedures.
- Ability to understand the nature of this trial and give written informed consent.
Exclusion Criteria:
- Known anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) "activating" mutations where first-line treatment with targeted tyrosine kinase inhibitor therapy is more appropriate.
- Known central nervous system (CNS) disease other than neurologically stable, treated brain metastases defined as metastasis having no evidence of progression or hemorrhage after treatment and no ongoing requirements for corticosteroids, (e.g., dexamethasone) for at least 2 weeks.
-
Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) ≥ Class 2:
- Unstable angina pectoris
- Congestive heart failure
- Acute myocardial infarction
- Conduction abnormality not controlled with pacemaker or medication
- Significant ventricular or supraventricular arrhythmias (Patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible).
- Patients currently receiving therapeutic anticoagulation.
- Pregnant or lactating women.
- Any serious, active underlying medical condition that would impair the ability of the patient to receive study treatment, such as diabetes mellitus or infection.
- Unable or unwilling to take folic acid or vitamin B12.
- Active second malignancy (except non-melanomatous skin or superficial bladder cancer) defined as requiring current need for cancer therapy or at high risk of recurrence (>30%) during the study.
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- Inability or unwillingness to comply with trial and/or follow-up procedures outlined in the protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01829113
United States, Colorado | |
Rocky Mountain Cancer Center | |
Denver, Colorado, United States, 80218 | |
United States, Florida | |
Florida Cancer Specialists-South | |
Fort Myers, Florida, United States, 33916 | |
Florida Hospital Cancer Insitute | |
Orlando, Florida, United States, 32804 | |
Florida Cancer Specialists-North | |
Saint Petersburg, Florida, United States, 33705 | |
United States, Kentucky | |
Baptist Hospital East | |
Louisville, Kentucky, United States, 40207 | |
United States, Maryland | |
Center for Cancer and Blood Disorders | |
Bethesda, Maryland, United States, 20817 | |
United States, Missouri | |
Research Medical Center | |
Kansas City, Missouri, United States, 64132 | |
United States, Nebraska | |
Nebraska Methodist Hospital | |
Omaha, Nebraska, United States, 68114 | |
United States, New Jersey | |
Hematology-Oncology Associates of Northern NJ | |
Morristown, New Jersey, United States, 07932 | |
United States, Ohio | |
Oncology Hematology Care, Inc. | |
Cincinnati, Ohio, United States, 45242 | |
United States, South Carolina | |
South Carolina Oncology Associates | |
Columbia, South Carolina, United States, 29210 | |
United States, Tennessee | |
Tennessee Oncology - Chattanooga | |
Chattanooga, Tennessee, United States, 37404 | |
Tennessee Oncology | |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
The Center for Cancer and Blood Disorders | |
Fort Worth, Texas, United States, 76104 | |
United States, Virginia | |
Peninsula Cancer Institute | |
Newport News, Virginia, United States, 23601 | |
Virginia Cancer Institute | |
Richmond, Virginia, United States, 23230 |
Study Chair: | David R. Spigel, M.D. | SCRI |
Documents provided by SCRI Development Innovations, LLC:
Responsible Party: | SCRI Development Innovations, LLC |
ClinicalTrials.gov Identifier: | NCT01829113 |
Other Study ID Numbers: |
SCRI LUN 229 |
First Posted: | April 11, 2013 Key Record Dates |
Results First Posted: | June 8, 2018 |
Last Update Posted: | June 8, 2018 |
Last Verified: | June 2018 |
Recurrent Lung Cancer Stage IV Lung Cancer OGX-427 Sarah Cannon Research Institute |
SCRI OncoGenex NSCLC Non Small Cell Lung Cancer |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |